Recruiting Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma NCT06947928 Conditions Adenocarcinoma, Advanced Or Metastatic Merkel Cell Carcinoma, Carcinoma, +22 more Locations USC Norris Comprehensive Cancer Center — Los Angeles, California, United States University of California San Francisco - Helen Diller Family Comprehensive Cancer Center — San Francisco, California, United States Stanford Health Care - Skin Cancer Program — Stanford, California, United States University of Colorado Hospital - Anschutz Cancer Pavilion — Aurora, Colorado, United States View all 18 locations View more locations Show fewer locations Loading locations... View Trial Details
Recruiting IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC) NCT06940440 Conditions Adenocarcinoma, Advanced Or Metastatic Merkel Cell Carcinoma, Carcinoma, +18 more Locations H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida, United States University of Wisconsin Carbone Cancer Center — Madison, Wisconsin, United States View Trial Details
